Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis.
Document Type
Article
Publication Date
5-2024
Abstract
PURPOSE: To facilitate claims-based research on populations with juvenile idiopathic arthritis (JIA), we sought to validate an algorithm of new medication use as a proxy for worsening JIA disease activity.
METHODS: Using electronic health record data from three pediatric centers, we defined new JIA medication use as (re)initiation of disease-modifying antirheumatic drugs or glucocorticoids (oral or intra-articular). Data were collected from 201 randomly selected subjects with (101) or without (100) new medication use. We assessed the positive predictive value (PPV) and negative predictive value (NPV) based on a reference standard of documented worsening of JIA disease activity. The algorithm was refined to optimize test characteristics.
RESULTS: Overall, the medication-based algorithm had suboptimal performance in representing worsening JIA disease activity (PPV 69.3%, NPV 77.1%). However, algorithm performance improved for definitions specifying longer times after JIA diagnosis (≥1-year post-diagnosis: PPV 82.9%, NPV 80.0%) or after initiation of prior JIA treatment (≥1-year post-treatment: PPV 89.7%, NPV 80.0%).
CONCLUSION: An algorithm for new JIA medication use appears to be a reasonable proxy for worsening JIA disease activity, particularly when specifying new use ≥1 year since initiating a prior JIA medication. This algorithm will be valuable for conducting research on JIA populations within administrative claims databases.
Publication Title
Pharmacoepidemiology and drug safety
Volume
33
Issue
5
First Page
5803
Last Page
5803
Recommended Citation
Saito, K., Gabbeta, A., Mulvihill, E., Al-Jaberi, L., Beukelman, T., Lewis, J., Rose, C., Strom, B., & Horton, D. (2024). Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis.. Pharmacoepidemiology and drug safety, 33 (5), 5803-5803. https://doi.org/https://doi.org/10.1002/pds.5803